Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

4D Molecular Therapeutics (FDMT) Operating Expenses (2020 - 2025)

Historic Operating Expenses for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Q3 2025 value amounting to $61.3 million.

  • 4D Molecular Therapeutics' Operating Expenses rose 1982.99% to $61.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $230.5 million, marking a year-over-year increase of 3688.16%. This contributed to the annual value of $187.9 million for FY2024, which is 4063.78% up from last year.
  • Latest data reveals that 4D Molecular Therapeutics reported Operating Expenses of $61.3 million as of Q3 2025, which was up 1982.99% from $59.5 million recorded in Q2 2025.
  • 4D Molecular Therapeutics' 5-year Operating Expenses high stood at $61.3 million for Q3 2025, and its period low was $18.3 million during Q1 2021.
  • For the 5-year period, 4D Molecular Therapeutics' Operating Expenses averaged around $36.8 million, with its median value being $32.4 million (2023).
  • Data for 4D Molecular Therapeutics' Operating Expenses shows a peak YoY increase of 5768.85% (in 2021) and a maximum YoY decrease of 892.22% (in 2021) over the last 5 years.
  • Quarter analysis of 5 years shows 4D Molecular Therapeutics' Operating Expenses stood at $24.9 million in 2021, then grew by 20.56% to $30.0 million in 2022, then grew by 22.24% to $36.6 million in 2023, then soared by 53.19% to $56.1 million in 2024, then rose by 9.19% to $61.3 million in 2025.
  • Its Operating Expenses was $61.3 million in Q3 2025, compared to $59.5 million in Q2 2025 and $53.6 million in Q1 2025.